Fangsheng Pharmaceutical released its 2026 interim report. Total operating revenue was 958 million yuan, net profit attributable to the parent company was 198 million yuan, and net cash inflow from operating activities was 270 million yuan. The company's latest asset-liability ratio was 39.57%, gross margin was 75.81%, return on equity was 11.12%, and diluted earnings per share was 0.45 yuan. Total asset turnover was 0.31 times, and inventory turnover was 0.67 times. The number of shareholders was 23,700, and the top ten shareholders held 46.76% of the total share capital.
Hunan Fangsheng Pharm Co LtdNet profit of 198 million yuan reported in interim results.